Holen Sie sich die Stockscreener-App
110.62
0.42%
-0.2407
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SRPT?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$110.86
Offen:
$110.87
24-Stunden-Volumen:
65,101
Relative Volume:
0.08
Marktkapitalisierung:
$10.51B
Einnahmen:
$1.50B
Nettoeinkommen (Verlust:
$47.30M
KGV:
-14.13
EPS:
-7.83
Netto-Cashflow:
$-527.92M
1W Leistung:
+1.17%
1M Leistung:
-13.29%
6M Leistung:
-14.51%
1J Leistung:
+31.29%
1-Tages-Spanne:
$109.11
$111.78
1-Wochen-Bereich:
$102.16
$111.78
52-Wochen-Spanne:
$78.67
$173.25
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Firmenname
Sarepta Therapeutics Inc
Sektor
Branche
Telefon
617-274-4000
Adresse
215 FIRST STREET, CAMBRIDGE, MA
Vergleichen Sie SRPT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| SRPT | 110.17 | 10.51B | 1.50B | 47.30M | -527.92M | -7.83 |
| VRTX | 447.95 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 741.90 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.12 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.68 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.56 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-01-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-12-13 | Fortgesetzt | Citigroup | Buy |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-11-21 | Eingeleitet | Wedbush | Outperform |
| 2023-10-31 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-06-23 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Outperform |
| 2023-04-04 | Eingeleitet | Citigroup | Buy |
| 2023-03-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | Bestätigt | BTIG Research | Buy |
| 2022-12-16 | Hochstufung | UBS | Neutral → Buy |
| 2022-04-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-01-05 | Bestätigt | Needham | Buy |
| 2021-12-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-11-05 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-09-15 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-08-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-01-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-01-11 | Herabstufung | UBS | Buy → Neutral |
| 2021-01-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2021-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | Eingeleitet | Berenberg | Hold |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-08-20 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | Eingeleitet | Mizuho | Buy |
| 2019-11-01 | Eingeleitet | Guggenheim | Buy |
| 2019-08-21 | Bestätigt | Needham | Buy |
| 2019-07-09 | Bestätigt | Morgan Stanley | Overweight |
| 2019-07-01 | Bestätigt | RBC Capital Mkts | Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-11 | Bestätigt | Credit Suisse | Outperform |
| 2018-10-12 | Eingeleitet | Bernstein | Outperform |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-26 | Bestätigt | RBC Capital Mkts | Outperform |
| 2018-09-14 | Fortgesetzt | BofA/Merrill | Buy |
| 2018-09-06 | Eingeleitet | Credit Suisse | Outperform |
| 2018-08-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | Bestätigt | Robert W. Baird | Outperform |
| 2018-06-20 | Bestätigt | Needham | Buy |
| 2018-06-19 | Bestätigt | H.C. Wainwright | Buy |
Alle ansehen
Sarepta Therapeutics Inc Aktie (SRPT) Neueste Nachrichten
SRPT Beats on Q3 Earnings & Sales, Discontinues PPMO-Based DMD Program - MSN
S&P 500 Futures Climb in Premarket Trading; Target, Fabrinet Lag - Barron's
Sarepta upgraded at Cantor on pipeline, growth potential - MSN
Sarepta Therapeutics (NASDAQ:SRPT) Cut to Hold at StockNews.com - MarketBeat
Braun Stacey Associates Inc. Grows Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Thrivent Financial for Lutherans Trims Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
FDA endorses speedy approval path for Regenxbio Duchenne gene therapy - Yahoo Finance
Cantor Fitzgerald Upgrades Sarepta Therapeutics (SRPT) - MSN
Aigen Investment Management LP Lowers Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Purchased by Mizuho Markets Americas LLC - MarketBeat
Sarepta Therapeutics, Inc. (SRPT): Among 12 High Growth Large Cap Stocks to Buy Now - Insider Monkey
Simplify Asset Management Inc. Buys 88,474 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
12 High Growth Large Cap Stocks to Buy Now - Insider Monkey
Relative Strength Alert For Sarepta Therapeutics - Nasdaq
Janus Henderson Group PLC's Strategic Acquisition in Sarepta The - GuruFocus.com
Capital International Investors Expands Stake in Sarepta Therape - GuruFocus.com
Sarepta Therapeutics' SWOT analysis: stock poised for growth amid DMD market leadership - Investing.com
Gene Therapy For Rare Disease Market Growth Demand, Segment - openPR
Sarepta Therapeutics (NASDAQ:SRPT) Is Posting Healthy Earnings, But It Is Not All Good News - Simply Wall St
Why Sarepta Therapeutics' (NASDAQ:SRPT) Earnings Are Weaker Than They Seem - Yahoo Finance
Sarepta stops development of exon 51-skipping therapy for DMD - Muscular Dystrophy News
Sarepta recent weakness brings buying opportunity, says JPMorgan - Yahoo Finance
Assetmark Inc. Acquires 27,220 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Principal Financial Group Inc. Decreases Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Sarepta halts development of Duchenne drug as Elevidys soars - The Pharma Letter
Oligonucleotide Therapy Market to Witness Huge Growth by 2031: - openPR
Sarepta Therapeutics: BLA Filing Of SRP-9003 For LGMD Is The Next Step (NASDAQ:SRPT) - Seeking Alpha
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Position Reduced by Fiera Capital Corp - MarketBeat
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q3 2024 Earnings Call Transcript - Insider Monkey
Sarepta price target lowered to $193 from $200 at Baird - Yahoo Finance
Sarepta’s Elevidys Sales Surge, But Next-Gen DMD Drug Platform Discontinued - Citeline
Sparked by FDA expansion, Sarepta's Elevidys takes another leap in sales - FiercePharma
Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 7.6% After Analyst Downgrade - MarketBeat
Sarepta Therapeutics (NASDAQ:SRPT) Price Target Raised to $150.00 - MarketBeat
Robert W. Baird Lowers Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $193.00 - MarketBeat
Sarepta sees strong sales on approved Duchenne treatment, stops work on clinical-stage drug - The Business Journals
Sarepta scraps a Duchenne drug as gene therapy sales rise - BioPharma Dive
Sarepta Therapeutics (NASDAQ:SRPT) Price Target Cut to $170.00 by Analysts at Evercore ISI - MarketBeat
Sarepta Halts Development of Next-Gen DMD Drug, Reports Robust Elevidys Sales - BioSpace
Sarepta Therapeutics' (SRPT) Buy Rating Reaffirmed at Needham & Company LLC - MarketBeat
Sarepta Therapeutics To Rally Around 30%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
Van ECK Associates Corp Has $8.85 Million Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Sarepta Therapeutics (NASDAQ:SRPT) Stock Rating Upgraded by Cantor Fitzgerald - MarketBeat
Sarepta Therapeutics (SRPT) Q3 2024 Earnings Call Transcript - Barchart
Sarepta pulls plug on Duchenne exon-skipping drug - pharmaphorum
Sarepta reports strong 3rd-qtr 2024 sales growth - The Pharma Letter
Sarepta Therapeutics Inc (SRPT) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Challenges - GuruFocus.com
Sarepta Therapeutics Inc (SRPT) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Sarepta Therapeutics Announces Third Quarter 2024 Financial Results and Recent Corporate Developments - BioSpace
Sarepta Therapeutics: Q3 Earnings Snapshot - Barchart
Finanzdaten der Sarepta Therapeutics Inc-Aktie (SRPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.42%
0.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):